insights_auto
Outlook: 51.7% bullish·6.9% bearish
Go to analysischevron_right
CSL:ASX
CSL Ltd
A$200.77
arrow_downward
-0.63%(-1.27) 1D
Nov 9, 4:11:00 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CSL...
Open
A$200.06
High
A$202.30
Low
A$199.62
Mkt. cap
96.35B
Avg. vol.
1.02M
Volume
893.44K
Dividend
1.41%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 9, 2025
52-wk high
A$203.13
52-wk low
A$90.00
EPS
-A$7.72
Shares outstanding
479.88M
No. of employees
29K
Open
A$200.06
High
A$202.30
Low
A$199.62
Mkt. cap
96.35B
Avg. vol.
1.02M
Volume
893.44K
Dividend
1.41%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 9, 2025
52-wk high
A$203.13
52-wk low
A$90.00
EPS
-A$7.72
Shares outstanding
479.88M
No. of employees
29K
News stories
From web sources and news partners
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees29K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorHealth Care
IndustryBiotechnology
Websitecsl.com